<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14799">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677208</url>
  </required_header>
  <id_info>
    <org_study_id>DH20120423</org_study_id>
    <nct_id>NCT01677208</nct_id>
  </id_info>
  <brief_title>Danhong Injection in the Treatment of Acute Ischemic Stroke</brief_title>
  <official_title>A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China  Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China: State Food and Drug Administration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China  Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <authority>China: Ministry of Science and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Danhong injection is effective in the
      treatment of acute ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Modified Rankin Scale 0-1 (favourable outcome) at Day 90</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Score of effect on symptoms of &quot;Xueyue Zheng&quot;(Blood Stasis syndrome)</measure>
    <time_frame>Day 0, Day7, Day 14, Day 30, Day 60, Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index score ≥90</measure>
    <time_frame>Day 0, Day7, Day 14, Day 30, Day 60, Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH stroke scale(NIHSS)</measure>
    <time_frame>Day 0, Day7, Day 14, Day 30, Day 60, Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>The improvement of the NIHSS score ≥4 or the NIHSS score of 0 to 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D scale</measure>
    <time_frame>Day 0, Day 7, Day 14, Day 30, Day 60, Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global disability on mRS at Day 90.</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of patients with mRS ≥3 at Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new-onset major vascular events in 90 days</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality at day 90</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hemorrhages in 90 days</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The definition of &quot;Severe hemorrhages&quot; is in accordance with the GUSTO bleeding criteria, including fatal intracranial hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) or which could result in substantial hemodynamic compromise requiring treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate hemorrhages in 90 days</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The definition of &quot;moderate hemorrhages&quot; is in accordance with the GUSTO bleeding criteria, which requires blood transfusion but not results in hemodynamic compromise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of adverse events (AEs) and serious AEs</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The changes on the profiles of micro-RNA in 96 patients selected from certain centers</measure>
    <time_frame>Day 0, Day 14, Day 90</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>The changes on the expression profiles of mRNA in 96 patients selected from certain centers</measure>
    <time_frame>Day 0, Day 14, Day 90</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">846</enrollment>
  <condition>Acute Stroke</condition>
  <arm_group>
    <arm_group_label>Danhong injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danhong injection</intervention_name>
    <description>A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion</description>
    <arm_group_label>Danhong injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard medical care</intervention_name>
    <description>Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.</description>
    <arm_group_label>Danhong injection</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.9% saline added into 250ml 0.9% saline by an independent research nurse,   sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male inpatients

          -  Age: 18 - 70 years.

          -  Clinical diagnosis of ischemic stroke causing a measurable neurological deficit
             defined as impairment of language, motor function, cognition and/or gaze, vision or
             neglect. Ischemic stroke is defined as an event characterized by the sudden onset of
             an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT
             scan excludes hemorrhage.

          -  Clinical diagnosis of &quot;Xueyu Zheng&quot; (Blood Stasis Syndrome) as the scores of Chinese
             medicine symptoms scales of &quot;Xueyu Zheng&quot; in ischemic stroke ≥ 20. The Chinese
             medicine symptoms scales of &quot;Xueyu Zheng&quot; is defined as following
             (1)hemiplegia-10,(2)numbness of limbs-10，(3) dark face-9,(4)purple or dark
             lip-8,(5)Roughness of skin-4, (6) pain with fixed point-5, (7) purple or dark
             tongue-10,(8)ecchymosis on tongue-10,(9)purple sublingual vessel-10,(10)varicose
             sublingual vessel-8,(11)unsmooth pulse-8,(12)intermittent pulse-1.

          -  Onset of symptoms in 1 week prior to initiation of administration of study drug.

          -  Clinical diagnosis of cerebral anterior circulation obstruction.

          -  4≤NIHSS＜20.

          -  Patient is willing to participate voluntarily and to sign a written patient informed
             consent. Informed consent will be obtained from each patient or the subject's legally
             authorized representative or relatives, or deferred where applicable, according to
             the regulatory and legal requirements of the participating centers.

        Exclusion Criteria:

          -  Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular
             malformation, tumor, abscess or multiple sclerosis etc.)on the CT-or MRI-scan.

          -  Patients with thrombolysis or endovascular treatment.

          -  Known history of allergy or suspected allergic to the drug.

          -  Blood glucose 2.8 or &gt; 16.8 mmol / l under the treatment of diabetes or with severe
             complications due to diabetes (eg. peripheral neuropathy, diabetic gangrene).

          -  Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.

          -  Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value.

          -  Severe cardiac dysfunction on echocardiogram or the grade of heart function over Ⅲ
             grade.

          -  History of prior stroke with mRS ≥2.

          -  Complicated with atrial fibrillation.

          -  Severe stroke as assessed by appropriate imaging techniques (eg. massive cerebral
             infarction including more than one lobe of brain or over 1/3 of blood-supply area of
             middle cerebral artery).

          -  Prior disable patients.

          -  Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.

          -  Suspected addicted into alcohol or drug abuse.

          -  With severe complications that would make the condition more complicated assessed by
             the investigator.

          -  Woman with pregnancy, lactation or positive result of pregnancy test, or women who
             want to be pregnant in recent 6 months.

          -  Woman who is under menstrual period.

          -  Patient who is participating in other trials or has been participated in other trials
             in recent 3 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xing-quan Zhao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong-yan Wang, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiao-xi Du, Professor</last_name>
    <role>Study Director</role>
    <affiliation>China: State Food and Drug Administration</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong Wang, Professor</last_name>
    <phone>8610-64014411</phone>
    <phone_ext>3308</phone_ext>
    <email>zhonw@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Liu, Ph.D.</last_name>
    <phone>8610-64014411</phone>
    <phone_ext>2805</phone_ext>
    <email>franlj1104@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Artillery General Hospital of People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Wang, Professor</last_name>
      <phone>8610-66343392</phone>
      <email>hellowanglei068@163.com</email>
    </contact>
    <investigator>
      <last_name>Lei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu-qiong Zhang, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Shu-qiong Zhang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital of Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qing-wu Yang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Qing-wu Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of T.C.M.</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin-zhi Wang, Professor</last_name>
      <phone>86371-66201040</phone>
      <email>znqznq@163.com</email>
    </contact>
    <investigator>
      <last_name>Xin-zhi Wang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Provincial Hospital of T.C.M.</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao-hui Zhang, M.D.</last_name>
      <phone>8627-88041919</phone>
      <phone_ext>82143</phone_ext>
    </contact>
    <investigator>
      <last_name>Zhao-hui Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-min Liu, M.D.</last_name>
      <phone>8627-67813086</phone>
    </contact>
    <investigator>
      <last_name>Yu-min Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second people's hospital of Hunan Province</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiu-ting Liu, Professor</last_name>
      <email>13974809911@163.com</email>
    </contact>
    <investigator>
      <last_name>Qiu-ting Liu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changsha Central Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu-xin Liu, Professor</last_name>
      <phone>86-13975128927</phone>
    </contact>
    <investigator>
      <last_name>Zhu-xin Liu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central-south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai-min Wang, Professor</last_name>
      <email>wangaimindoc@163.com</email>
    </contact>
    <investigator>
      <last_name>Ai-min Wang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Xu, M.D.</last_name>
      <phone>8625-83305616</phone>
      <phone_ext>20802</phone_ext>
      <email>xuyunz@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yun Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Hospital of T.C.M.</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu-ping Cao, Professor</last_name>
      <phone>86-13951014652</phone>
    </contact>
    <investigator>
      <last_name>Shu-ping Cao, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-qiang Gao, Professor</last_name>
      <phone>86-18951762858</phone>
    </contact>
    <investigator>
      <last_name>Zhi-qiang Gao, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting-min Yu, M.D.</last_name>
      <phone>86-431-88796816</phone>
    </contact>
    <investigator>
      <last_name>Ting-min Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Zhongshan Hospital of Dalian University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Ma, Professor</last_name>
      <phone>86411-62893581</phone>
      <email>mqiang2100@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Qiang Ma, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shanghai City</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qing-ping Huo, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Qing-ping Huo, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuhui District Central Hospital of Shanghai City</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital to Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang-lai Li, Professor</last_name>
      <phone>86-13703587193</phone>
    </contact>
    <investigator>
      <last_name>Guang-lai Li, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The PLA Fourth Fifty-one Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-yi Chi, Professor</last_name>
      <email>1173319088@qq.com</email>
    </contact>
    <investigator>
      <last_name>Li-yi Chi, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710068</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Yang, Professor</last_name>
      <email>YangQdoctor@163.com</email>
    </contact>
    <investigator>
      <last_name>Qian Yang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Province Hospital of T.C.M.</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zu-cheng Han, Professor</last_name>
      <email>13759968645@139.com</email>
    </contact>
    <investigator>
      <last_name>Zu-cheng Han, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Shanxi University of Chinese Medicine</name>
      <address>
        <city>Xianyang</city>
        <state>Shanxi</state>
        <zip>712000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-mei Yan, Professor</last_name>
      <phone>86-13609216551</phone>
    </contact>
    <investigator>
      <last_name>Yong-mei Yan, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital of Chengdu University of Traditional Chinese Medicine</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Lu</last_name>
      <email>luyun999@126.com</email>
    </contact>
    <investigator>
      <last_name>Yun Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300193</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-hong Meng, M.D.</last_name>
      <phone>86-18722699933</phone>
    </contact>
    <investigator>
      <last_name>Zhi-hong Meng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial Hospital of T.C.M.</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Hou, Professor</last_name>
      <email>houqun168@163.com</email>
    </contact>
    <investigator>
      <last_name>Qun Hou, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ben-yan Luo, M.D.</last_name>
      <email>luobenyan@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ben-yan Luo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Geng, M.D.</last_name>
      <email>gengy2004@126.com</email>
    </contact>
    <investigator>
      <last_name>Yu Geng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital of Zhejiang Province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Xu, Professor</last_name>
      <phone>86-571-85288221</phone>
    </contact>
    <investigator>
      <last_name>Bin Xu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuan Wu Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Gao, Professor</last_name>
      <phone>8610-83198728</phone>
      <email>xuanwugaoli@126.com</email>
    </contact>
    <investigator>
      <last_name>Li Gao, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tiantan Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xing-quan Zhao, M.D.</last_name>
      <phone>010-67098891</phone>
      <email>zxq@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Xing-quan Zhao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xue-zhi Zhang, Professor</last_name>
      <phone>010-83572634</phone>
      <email>zhang.xuezhi@263.net</email>
    </contact>
    <investigator>
      <last_name>Xue-zhi Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China  Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zhong Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
